Mutations of the β2-microglobulingene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides
| Autor: | Guy Andry, Francisco Ruiz-Cabello, Francis Brasseur, F. Garrido, Danièle Godelaine, Teresa Cabrera, M.A. López-Nevot, M. R. Oliva, Nicolas van Baren, Maurice Marchand, R. Benitez, Thierry Boon, Claire Landry, Pilar Jiménez |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Molecular Sequence Data
Immunology Antigen presentation Human leukocyte antigen Biology medicine.disease_cause Cancer Vaccines Biochemistry Gene product Loss of heterozygosity Start codon Antigens Neoplasm Tumor Cells Cultured Genetics medicine Humans Immunology and Allergy Melanoma Vaccines Synthetic Mutation Base Sequence Beta-2 microglobulin Histocompatibility Antigens Class I General Medicine medicine.disease Neoplasm Proteins Female Peptides beta 2-Microglobulin Melanoma-Specific Antigens |
| Zdroj: | Tissue Antigens. 52:520-529 |
| ISSN: | 1399-0039 0001-2815 |
| DOI: | 10.1111/j.1399-0039.1998.tb03082.x |
| Popis: | Mutations have been identified in the beta2-microglobulin gene of tumor cells of two metastatic melanoma patients who received immunizations with MAGE peptides. One mutation abolishes the start codon whereas the other introduces a premature stop codon. The second beta2-microglobulin allele of both tumors appears to be lost on the basis of sequence data and loss of microsatellite heterozygosity. The lack of beta2-microglobulin gene product results in the absence of HLA class I antigens on the surface of the tumor cells. This may explain why the tumors of both patients progressed despite the immunization treatment and shows the necessity of analyzing in depth the antigen presentation capability of the tumor cells for the interpretation of clinical trials involving anti-tumor vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text